Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
OPRX
OPRX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
OPRX News
OptimizeRx Partners with Experian to Enhance DTC Marketing Effectiveness
Jan 07 2026
Globenewswire
OptimizeRx Expands POC Network with Four New Partner Agreements, Increasing NPI Reach by 37%
Dec 17 2025
Globenewswire
OptimizeRx Expands NPI Reach by 37% with Four New Partner Agreements
Dec 17 2025
Newsfilter
Ophirex Secures FDA Agreement for Varespladib Snakebite Treatment Development
Dec 11 2025
Globenewswire
Stephens & Co. Keeps Equal-Weight Rating on OptimizeRx, Reduces Price Target to $17
Nov 17 2025
Benzinga
Top Strong Buy Stocks for November 17: ROKU, AVPT, and Others
Nov 17 2025
NASDAQ.COM
Transcript of OptimizeRx (OPRX) Earnings Call for Q3 2025
Nov 10 2025
NASDAQ.COM
OptimizerRx sets 2026 revenue goal between $118M and $124M, driven by early contract insights and digital pharmaceutical growth.
Nov 07 2025
SeekingAlpha
Reasons to Consider OptimizeRx Corp. (OPRX) as a Strong Momentum Stock: Is It Time to Buy?
Sep 01 2025
NASDAQ.COM
Stifel Maintains Buy on OptimizeRx, Raises Price Target to $18
Aug 08 2025
Benzinga
Why Expedia Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Aug 08 2025
Benzinga
OptimizeRx Stock Rallies 22% After-Hours Thanks To Q2 Earnings Push
Aug 08 2025
Benzinga
OPRX Delivers Solid Q1 Earnings: But Can It Sustain the Momentum?
Jul 25 2025
NASDAQ.COM
‘Story’ stocks are smoking hot in 2025. How it could end badly for investors.
Jul 12 2025
MarketWatch
OptimizeRx Bets on AI and Workflow Integration: Will This Pay Off?
Jul 11 2025
NASDAQ.COM
This fund returned 21% in May alone buying ‘left-for-dead’ stocks — and it has a new target
Jul 01 2025
MarketWatch
Show More News
